• (PLX AI) – Merck KGaA announces Definitive Agreement to Acquire Exelead.
  • • Says will strengthen Merck’s CDMO offering for mRNA
  • • Merck KGaA to acquire Exelead for approximately USD 780 million in cash
  • • Exelead, a full-service CDMO, focusing on Lipid Nanoparticle formulations enhances Merck’s mRNA and lipid manufacturing capabilities
  • • Exelead specializes in complex injectable formulations, including Lipid Nanoparticle (LNP) based drug delivery technology which is key in mRNA therapeutics for use in Covid-19 and many other indications
  • • The transaction is expected to close in the first quarter of 2022

Quelle: PLX AI